medigraphic.com

2009, Número 1

<< Anterior

Rev Med Hosp Gen Mex 2009; 72 (1)


Enfermedad psiquiátrica y síndrome metabólico. Énfasis en el trastorno esquizofrénico

Joffre-Velázquez VM, García-Maldonado G, Saldívar-González AH, Lin-Ochoa D, Sosa-Herrera J

Idioma: Español
Referencias bibliográficas: 99
Paginas: 41-49
Archivo PDF: 99.15 Kb.


RESUMEN

Introducción: La mayoría de las personas con esquizofrenia presentan disturbios metabólicos. Objetivo: Revisar y describir los avances científicos relacionados con el síndrome metabólico, la esquizofrenia y la comorbilidad entre estos trastornos. Método: Se recurrió a las bases de datos PubMed, EbscoHost y OvidSP, incluyendo estudios de investigación relevantes publicados en idioma inglés en los últimos 10 años. Resultados: La incidencia de la esquizofrenia en promedio es de 15.2 casos en 100,000 personas por año, y la prevalencia del síndrome metabólico rebasa el 20%, que se incrementa con la edad hasta en más del 40%. La asociación de estos dos trastornos conforma un problema de salud pública, y en la actualidad algunos estudios reportan la comorbilidad en más del 70% de casos. Conclusión: Es necesaria una estricta vigilancia para prevenir la aparición de este síndrome en el paciente esquizofrénico.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Informe sobre la salud en el mundo. Organización Mundial de la Salud. 2001 Salud mental: nuevos conocimientos, nuevas esperanzas. Disponible en: http: //www.who.int/whr/2001/en/whr01_es.pdf

  2. ICD-10 Classification of Mental and Behavioural Disorders: Clinical descriptions and diagnostic guidelines. Health World Organization 1992.

  3. Pineda C. Síndrome metabólico: definición, historia, criterios. Colomb Med 2008; 39: 96-106.

  4. Medina-Mora ME, Borges G, Lara MC, Benjet C, Blanco JJ, Fleiz BC et al. Prevalencia de trastornos mentales y uso de servicios: resultados de una Encuesta Nacional de Epidemiología Psiquiátrica en México. Salud Mental 2003; 26: 1-16.

  5. Robertson GS, Hori SE, Powell KJ. Schizophrenia: An integrative approach to modeling a complex disorder. J Psychiatry Neurosci 2006; 31: 157-167.

  6. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. Plos Med 2005; 2: 413-433.

  7. Olsen L, Hansen T, Jakobsen KD, Djurovic S, Melle I, Agartz I et al. The estrogen hypothesis of Schizophrenia implicates glucose metabolism: Association study in three independent samples. Med Genet 2008; 9: 1-13

  8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC; 2000.

  9. Mendoza BF. Síndrome metabólico, tratamiento y riesgo de diabetes mellitus. Acta Neurol Colomb 2007; 23: 77-89.

  10. Qin P, Xu H, Laursen TM, Vestergaard M. Risk for Schizophrenia and schizophrenia-like psychosis among patients with epilepsy: Population based cohort study. BMJ 2005; 331: 1-6.

  11. Sevy S, Burdick KE, Visweswaraiah H, Abdelmessih S, Lukin M, Yechiam E et al. Iowa gambling task in schizophrenia: A review and new data in patients with schizophrenia and co-occurring cannabis use disorders. Schizophr Res 2007; 92: 74-84.

  12. Srisurapanont M, Likhitsathian S, Boonyanaruthee V, Jarusuraisin N. Metabolic syndrome in thai schizophrenic patients: a naturalistic one-year follow-up study. BMC Psychiatry 2007; 7: 1-6.

  13. Toalson P, Ahmed S, Hardy T, Kabinoff G. The Metabolic Syndrome in Patients With Severe Mental Illnesses. Prim Care Companion J Clin Psychiatry 2004; 6: 152-158.

  14. Pompili M, Amador XF, Girardi P, Harkavy-Friedman J, Harrow M, Kaplan K et al. Suicide risk in schizophrenia: learning from the past to change the future. Ann Gen Psychiatry 2007; 6: 1-22.

  15. M Lin, Curtis D, Williams N, Arranz M, Nanko S, Collier D et al. Suggestive evidence for linkage of schizophrenia to markers on chromosome 13q14.1-q32. Psychiatr Genet 1995; 5: 117–126.

  16. Blouin JL, Dombroski BA, Nath SK, Lasseter VK, Wolyniec PS, Nestadt G et al. Schizophrenia susceptibility loci on chromosomes 13q32 and 8p21. Nat Genet 1998; 20: 70–73.

  17. Brzustowicz LM, Honer WG, Chow EWC, Little D, Hogan J, Hodgkinson K et al. Linkage of familial schizophrenia to chromosome 13q32. Am J Hum Genet 1999; 65: 1096–1103.

  18. Schwab SG, Eckstein S, Hallmayer J, Lerer B, Albus M, Borrmann M et al. Evidence suggestive of a locus on chromosome 5q31 contributing to susceptibility for schizophrenia in German and Israeli families by multipoint affected sib-pair linkage analysis. Mol Psychiatry 1997; 2: 156-160.

  19. Straub RE, Maclean CJ, O’Neill FA, Walsh D, Kendler KS. Support for a possible schizophrenia vulnerability locus in region 5q22-31 in Irish families. Mol Psychiatry 1997; 2: 148–155.

  20. Schwab SG, Hallmayer J, Lerer B, Albus M, Borrmann M, Hönig S et al. Support for a chromosome 18p locus conferring susceptibility to functional psychoses in families with schizophrenia, by association and linkage analysis. Am J Hum Genet 1998; 63: 1139–1152.

  21. Faraone SV, Matise T, Svrakic D, Pepple J, Malaspina D, Suarez B et al. Genome scan of European-American schizophrenia pedigrees. Results of the NIMH Genetics Initiative and Millennium Consortium. Am J Med Genet 1998; 81: 290–295

  22. Schwab SG, Hallmayer J, Albus M. A potential susceptibility locus on chromosome 10p14-p11 in 72 families with schizophrenia. Am J Med Genet 1998; 81: 528–529.

  23. Straub RE, Maclean CJ, Martin RB, Ma Y, Myakishev MV, Harris-Kerr C et al. A schizophrenia locus may be located in region 10p15-p11. Am J Med Genet 1998; 81: 296–301.

  24. Cao Q, Martinez M, Zhang J, Sanders AR, Badner JA, Cravchik A et al. Suggestive evidence for a schizophrenia susceptibility locus on chromosome 6q and a confirmation in an independent series of pedigrees. Genomics 1997; 43: 1–8.

  25. Martinez M, Goldin LR, Cao Q, Zhang J, Sanders AR, Nancarrow DJ et al. Follow-up study on a susceptibility locus for schizophrenia on chromosome 6q. Am J Med Genet 1999; 88: 337–343.

  26. Brzustowicz LM, Hodgkinson KA, Chow EW, Honer WG, Bassett AS. Location of a major susceptibility locus for familial schizophrenia on chromosome 1q21-q22. Science 2000; 288: 678–682.

  27. Salgado-Pineda P, Vendrell P. La imagen por resonancia magnética en el estudio de la esquizofrenia. Anales de Psicología 2004; 20: 261-272.

  28. Realmuto G. Neurobiological Assessment. In: Klykylo M. Clinical Child Psychiatry Second Edition. New York: John Wiley & Sons; 2005. p. 49-65

  29. Bowden NA, Scott RJ, Tooney PA. Altered gene expression in the superior temporal gyrus in schizophrenia. BMC Genomics 2008; 9: 1-12.

  30. Mitelman SA, Brickman AM, Shihabuddin L, Newmark RE, Hazlett EA, Haznedar MM et al. A comprehensive assessment of gray and white matter volumes and their relationship to outcome and severity in schizophrenia. Neuroimage 2007; 37: 449-462.

  31. Løberg EM, Hugdahl K, Green MF. Hemispheric asymmetry in schizophrenia: a «dual deficits» model. Biol Psychiatry 1999; 45: 76-81.

  32. Weinberger DR, Berman KF. Speculation on the meaning of cerebral metabolic hypofrontality in schizophrenia. Schizophr Bull 1988; 14: 157-168.

  33. Ferrero RL, Pérez MI, Gómez PE, Loynaz FC, Rodríguez RA et al. Algunas características anatómicas del encéfalo del esquizofrénico. Rev Cubana Invest Biomed 2004; 23: 163-168.

  34. Van Gaal MF, Mertens I, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444: 875-880.

  35. Martins JM, Trinca A, Afonso A, Carreiras F, Falcão J, Nunes JS et al. Psychoneuroendocrine characteristics of common obesity clinical subtypes. Int J Obes Relat Metab Disord 2001; 25: 24-32.

  36. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.

  37. Ninomiya JK, L’Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS et al. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004; 109: 42-46.

  38. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. Third National Health and Nutrition Examination Survey (NHANES III), National Cholesterol Education Program (NCEP). NCEP-Defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52: 1210-1214.

  39. Palaniappan L, Carnethon M, Fortmann SP. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens 2003; 16: 952-958.

  40. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 2004; 140;167-174.

  41. Rutter MK, Meigs JB, Sullivan LM, D’Agostino RB, Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham offspring study. Circulation 2004; 110: 380-385.

  42. Sattar N, Gaw A, Scherbakova O, Ford I, O’Reilly DS, Haffner SM et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414-419.

  43. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: A 8-year follow-up of 14,719 initially healthy American women. Circulation 2003; 107: 391-397.

  44. Meigs JB, Wilson PW, Nathan DM, D’Agostino RB, Williams K, Haffner SM. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 2003; 52: 2160-2167.

  45. Ramachandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V. Metabolic syndrome in urban Asian Indian adults: a population study using modified ATP criteria. Diabetes Res Clin Pract 2003; 60: 199-204.

  46. Azizi F, Salehi P, Etemadi A, Zahedi-Asl S. Prevalence of metabolic syndrome in an urban population: Tehran lipid and glucose study. Diabetes Res Clin Pract 2003; 61: 29-37.

  47. Aguilar SC, Rojas R, Gomez PF, Valles V, Rios TJ, Franco A et al. High Prevalence of metabolic syndrome in Mexico. Arch Med Res 2004; 35: 76-81.

  48. Ramírez VE, Arnaud VM, Delisle H. Prevalence of the metabolic syndrome and associated lifestyle in adult males from Oaxaca Mexico. Sal Pub Mex 2007; 49: 94-102.

  49. Kloting N, Bluher M, Kloting I. The polygenetically inherited metabolic syndrome of WOKW rats is associated with insulin resistance and altered gene expression in adipose tissue. Diab Metab Res Rev 2006; 22: 146-154.

  50. Barbier O, Pineda TI, Duguay Y, Blanquart C, Fruchart J-C, Glineur C et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2002; 22: 717-726.

  51. Grimaldi PA. Regulatory role of peroxisome proliferator activated receptor delta (PPAR delta) in muscle metabolism. A new target for metabolic syndrome treatment? Biochimie 2005; 87: 5–8.

  52. Shah KP, Kaul S, Nilsson J, Cercek B. Exploiting the Vascular Protective Effects of High-Density Lipoprotein and Its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part I. Circulation 2001; 104: 2376-2383.

  53. Calabresi L, Gomaraschi M, Franceschini G. Endotelial Protection by High-Density Lipoproteins: From Bench to Bedside. Arterioscler Thromb Vasc Biol 2003; 23: 1724-1731.

  54. Daskalopoulou SS, Atrios VG, Kolovou GD, Anagnostopoulou KK, Mikhailidis DP. Definitions of metabolic syndrome: Where are we now? Curr Vasc Pharmacol 2006; 4: 185-197.

  55. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eu Hearth J 2003; 24: 1601-1610.

  56. Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Executive summary of the Third Report of the National Cholesterol Education Program (NCEP). JAMA 2001; 285: 2486-2497.

  57. Grundy SM, Brewer HB, Cleeman JI, Smith SC. For the Conference Participants. Definition of Metabolic Syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004; 109: 433-438.

  58. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. For Conference Participants. Clinical Management of Metabolic Syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004; 109: 551-556.

  59. Balkau B, Charles MA, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin JS et al. The European Group For The Study Of Insulin Resistance [EGIR]. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002; 28: 364-376.

  60. Zimmet P, Alberti KG, Serrano RM. Una nueva definición mundial del síndrome metabólico propuesta por la Federación Internacional de Diabetes: fundamento y resultados. Rev Esp Cardiol 2005; 58: 1371-1376.

  61. Grundy SM, Cleeman JI, Daniela SR, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and Management of the Metabolic Syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.

  62. Newcomer JW. Metabolic syndrome and mental illness. Am J Manag Care 2007; 13: 170-177.

  63. Bermudes RA, Keck PE, Welge JA. The prevalence of the metabolic syndrome in psychiatric inpatients with primary psychotic and mood disorders. Psychosomatics 2006; 47: 491-497.

  64. Teixeira PJ, Rocha FL. The prevalence of metabolic syndrome among psychiatric in patients in Brazil. Rev Bras Psiquiatr 2007; 29: 330-336.

  65. Faglioni A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 2005; 7: 424-430.

  66. Thakore JH. Metabolic syndrome and schizophrenia. Br J Psychiatry 2005; 186: 455-456.

  67. Attux C, Quintana MI, Chaves AC. Weight gain, dyslipidemia and altered parameters for metabolic syndrome on first episode psychotic patients after six-month follow-up. Rev Bras Psiquiatr 2007; 29: 346-349.

  68. Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004; 292: 2237-2242.

  69. Usher K, Foster K, Park T. The metabolic syndrome and schizophrenia: the latest evidence and nursing guidelines for management. J Psychiatr Ment Health Nurs 2006; 13: 730-734.

  70. Citrome L, Blonde L, Damatarca C. Metabolic issues in patients with severe mental illness. Southern Med J 2005; 98: 714-720.

  71. Ozenoglu A, Ugurlu S, Balci H, Eker E. Nutritional approach to metabolic changes arising out of schizophrenia therapy: case report. Intern Med 2007; 46: 1213-1218.

  72. De Hert M, Van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health 2006; 2: 1-10.

  73. Kato MM, Currier MB, Gomez CM, Hall L, Gonzalez-Blanco M. Prevalence of Metabolic Syndrome in Hispanic and Non-Hispanic Patients With Schizophrenia. J Clin Psychiatr 2004; 6: 74-77.

  74. Heiskanen T, Niskanen L, Lyytikäinen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003; 64: 575-579.

  75. Holt RI, Peveler RC, Byrne CD. Schizophrenia, the metabolic syndrome and diabetes. Diabet Med 2004; 21: 515-523.

  76. Jacob R. Metabolic comorbidity in schizophrenia. Indian J Med Sci 2008; 62: 23-31.

  77. Kato MM, Currier MB, Villaverde O, Gonzalez-Blanco M. The relation between body fat distribution and cardiovascular risk factors in patients with schizophrenia: a cross-sectional pilot study. J Clin Psychiatr 2005; 7: 115-118.

  78. Kahn R, Buse J, Ferrannini E, Stern M. The Metabolic Syndrome: time for a critical appraisal. Diabetes Care 2005; 28: 2289–2304.

  79. Akbarian S, Ruehl MG, Bliven E, Luiz LA, Peranelli AC, Baker AP et al. Chromatin alterations associated with down-regulated metabolic gene expression in the prefrontal cortex of subjects with schizophrenia. Arch Gen Psychiatry 2005; 62: 829-840.

  80. Aranceta J, Foz M, Gil B, Joverd E, Mantilla T, Millán J et al. Documento de Consenso: Obesidad y riesgo cardiovascular. Clin Invest Arterioscl 2003; 15: 196-233.

  81. Banegas BJ, Ruilope LM. Epidemia de enfermedades metabólicas. Una llamada de atención. Med Clin [Barc] 2003; 120: 99-100.

  82. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 2002; 359: 2072-2077.

  83. Cohn T, Prud’homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 2004; 49: 753-760.

  84. Isomaa B, Alegren P, Tuomi T, Forsen B, Lahti K, Nissen M et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.

  85. Thompson PD, Buchner D, Pina IL, Balady GJ, Williams MA, Marcus BH et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease. Circulation 2003; 107: 3109-3116.

  86. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronar Prevention Study. Circulation 2001; 103: 357-362

  87. Elman I, Adler CM, Malhotra AK, Bir C, Pickar D, Breier A. Effect of Acute Metabolic Stress on Pituitary-Adrenal Axis Activation in Patients With Schizophrenia. Am J Psychiatry 1998; 155: 979-981.

  88. Keltner NL. Biological perspectives. Metabolic syndrome: schizophrenia and atypical antipsychotics. Perspective Psychiatr Care 2006; 42: 204-207.

  89. Ried LD, Renner BT, McConkey JR, Bengtson MA, Lopez LM. Increased cardiovascular risk with second-generation antipsychotic agent switches. J Am Pharm Assoc 2006; 46: 491-501.

  90. Nagamine T. Olanzapine-induced elevation of serum triglyceride levels in a normal weight patient with schizophrenia. Inter Med 2008; 47: 181-182.

  91. Fenton WS, Chavez MR. Medication-induced weight gain and dyslipidemia in patients with schizophrenia. Am J Psychiatry 2006; 163: 1697-1704.

  92. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223.

  93. McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004; 65: 47-56.

  94. Lieberman JA. Metabolic changes associated with antipsychotic use. J Clin Psychiatry 2004; 6: 8-13.

  95. Isomaa B, Alegren P, Tuomi T, Forsen B, Lahti K, Nissen M et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.

  96. Lieberman JA, Stroup S, McEvoy J, Schwartz MS, Rosenheck RA, Perkins DO et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223.

  97. Tuomilehto J. Cardiovascular risk: prevention and treatment of the metabolic syndrome. Diabetes Res Clin Pract 2005; 68: 28-35.

  98. Cerit C, Ozten E, Yildiz M. [The prevalence of metabolic syndrome and related factors in patients with schizophrenia]. Turk Psikiyatri Derg 2008; 19: 124-132.

  99. Ferranti SD, Gauvreau K, Ludwig DS, Neufeld EJ, Newburger JW, Rifai N. Prevalence of metabolic syndrome in american adolescents. Findings from the third national Health and Nutrition Examination Survey. Circulation 2004; 110: 2494-2497.




2020     |     www.medigraphic.com